Company's Signature Product Line Receives Positive Reviews
BOSTON, Oct. 23 /PINKSHEETS/ -- Solos Endoscopy, Inc. (Pink Sheets: SNDY- News)is pleased to announce that the Company has received additional purchase ordersfor its MammoView(TM) line of surgical endoscopy instruments from the NationalCancer Institute (NCI), as well as the U.S. National Institute of Health(NIOH), which is part of the U.S. Department of Health and Human Services.Solos Endoscopy's MammoView(TM) line of endoscopy surgical instruments hasreceived positive reviews from various surgeons who have been regularly usingthe instruments during their endoscopic procedures.
NCI is1 of 27 Institutes and Centers that comprise the U.S. National Institutes ofHealth. Located in Bethesda, Maryland, NIOH is the primary Federal agency forconducting and supporting medical research. Solos Endoscopy's MammoView(TM)system employs advanced micro endoscopes and optical technology to givephysicians sharp, clear images of the milk ducts where the majority of breastcancers arise.
"Thecytology retrieval kit which contains miniature brushes and a mini aspiratoris, in my opinion, the best method for retrieving cell samples from the liningof the mammary duct," stated David N. Danforth Jr., M.S., M.D., SurgeryBranch Senior Investigator from the National Institute of Health.
"Weare very pleased to continue supplying our MammoView(TM) surgical endoscopyinstruments to the top cancer care and research organizations in the country.We believe, as the body of research expands, more and more surgeons willutilize our system, which will enable them to detect possible cancerous cellsin its early stage and begin treatments immediately on their patients,"stated Bob Segersten, President of Solos Endoscopy, Inc.
SolosEndoscopy recently announced that the Company has taken the initial steps toget the CE Marking for its FDA approved MammoView(TM) line of surgicalinstruments. This will allow the MammoView(TM) line to be sold throughout theEuropean Economic Union (EEU), which represents 30% or $94 Billion of theworldwide demand for medical instruments.
Formore information on the National Cancer Institute, please visit: www.cancer.gov.
Formore information on the National Institute of Health, please visit: www.nih.gov.
AboutSolos Endoscopy, Inc.:
SolosEndoscopy, Inc. is a healthcare technology company whose mission is to developand market breakthrough technology, applications, medical devices andprocedural techniques for the screening, diagnosis, treatment and management ofmedical conditions. Backed by technical support, Solos' sales team can helpmake the right buying decisions for the hospital, surgery center, or physicianoffice with its catalog of FDA Approved products. Additional information isavailable on the Company's website at: www.solosendoscopy.com.
SafeHarbor: This release includes forward-looking statements within the meaning ofSection 27A of the Securities Act of 1933 and Section 27E of the Securities Actof 1934. Statements contained in this release that are not historical facts maybe deemed to be forward-looking statements. Investors are cautioned thatforward-looking statements are inherently uncertain. Actual performance andresults may differ materially from that projected or suggested herein due tocertain risks and uncertainties including, without limitation, ability toobtain financing and regulatory and shareholder approval for anticipatedactions.
Contact:
InvestorRelations
BigApple Consulting USA
1407-389-5900
Source: Solos Endoscopy, Inc.